Table 3 Clinical characteristics comparison between PD-L1 positive and negative expression in NSCLC patients
Variables | PD-L1 positive (n = 186) | PD-L1 negative (n = 199) | P |
|---|---|---|---|
Gender | 0.07 | ||
Male | 87 | 111 | |
Female | 99 | 88 | |
Age | 0.68 | ||
<60 | 102 | 105 | |
≥60 | 84 | 94 | |
Smoking status | 0.12 | ||
Never | 121 | 114 | |
Former/current | 65 | 85 | |
Pathologic stage | 0.09 | ||
I + II | 105 | 95 | |
III | 81 | 104 | |
EGFR | 0.008 | ||
Yes | 112 | 93 | |
No | 74 | 106 | |
ALK | 0.53 | ||
Yes | 10 | 8 | |
No | 176 | 191 | |
KRAS | 0.16 | ||
Yes | 5 | 11 | |
No | 181 | 188 | |
HER2 | 0.44 | ||
Yes | 6 | 3 | |
No | 180 | 196 | |
ROS1 | 0.65 | ||
Yes | 5 | 3 | |
No | 181 | 196 | |
PIK3CA | 0.74 | ||
Yes | 2 | 4 | |
No | 184 | 195 | |
RET | 0.74 | ||
Yes | 3 | 3 | |
No | 183 | 196 | |
BRAF | 0.45 | ||
Yes | 2 | 0 | |
No | 184 | 199 | |
NRAS | 0.97 | ||
Yes | 0 | 1 | |
No | 186 | 198 | |
Concurrent alteration | 0.01 | ||
Yes | 18 | 6 | |
No | 168 | 193 | |
Pan-negative | <0.01 | ||
Yes | 23 | 67 | |
No | 163 | 132 | |